Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes

Experimental and Clinical Endocrinology and Diabetes

Volumn 104, Issue 1, 1996, Pages 25-30

  Pfutzner A ^a,b   Kustner E ^a   Forst, T ^a   Schulze Schleppinghoff, B ^c   Trautmann, M E ^b   Haslbeck, M ^d   Schatz, H ^e   Beyer, J ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b LILLY DEUTSCHLAND GMBH   (Germany)

^c Ambulantes Diabeteszentrum   (Germany)

^d Klinikum Schwabing   (Germany)

^e RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Hypoglycemia; Insulin lispro; Type 1 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ANTIBODY; INSULIN DERIVATIVE; INSULIN LISPRO;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 9044233249     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1211418     Document Type: Article

References (23)

1. Amiel SA, Sherwin RS, Simonson DC, Tamborlane WV: Effect of instensive insulin therapy on glycemic thresholds for counterrgulatory hormone release. Diabetes, 37: 901-907, 1988
2. Binder C, Lauritzen T, Faber O, Pramming S: Insulin pharmacokinetics. Diabetes care 7: 188-199, 1984
3. Bolli G, Dimitriadis G, Pehling G et al.: Abnormal glucose counterregulation after subcutaneous insulin in insulin-dependent diabetes mellitus. N. Engl. J. Med., 310: 17061711, 1984
4. Bolli G: The pharmacokinetic basis of insulin therapy. Diab. Res. Clin. Pract. 6: S3-S16, 1989
5. Brange J, Owens DR, Kang S, Volund A: Monomeric insulins and their experimental and clinical implications. Diabetes care, 13: 923-954, 1990
6. Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW: Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. Diabetes 37: 736-744, 1988,
7. Dagogo-Jack SE, Craft S, Cryer PE: Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. J Clin Invest, 91: 819-828, 1993
8. DiMarchi RD, Mayer JP, Fan L, Brems DN, Frank BH, Green LK, Hoffmann JA, Howey DC, Long HB, Shaw WN, Shields JE, Slieker LJ, Su KS, Sundell K, Chance RE: Synthesis of a fast-acting insulin based on structural homology with insulin-like growth factor I. in Peptides XII (Proceedings of the 12th American Peptide Symposium). Smith J, Rivier J Eds. Leiden, Netherlands, B.V., 26-28, 1992
9. Dimitriadis G, Gehrich J: Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes care 8: 374-377, 1985
10. Fineberg NS, Fineberg SE, Anderson JH, Birkett M, Gibson RG, Hufferd S: Does Lyspro (B28,B29) human insulin anaolog have altered immunogenicity in patients with type 1 diabetes. Abstr. No. 07A5PP0396, 15th IDF Congress, Kobe, Japan 6.-11. Nov. 1994
11. Fineberg SE, Fineberg NS, Anderson JH, Birkett M: Insulin immune response to lyspro human insulin therapy in insulin naive type 1 and type 2 patients. Diabetologia, 38 (Suppl. 1): A4, 1995
12. Galloway JA: New directions in drug developement: mixtures, analogues, and modeling. Diabetes Care 16 (suppl.3): 16-23, 1993
13. Heller SR, Greyer PE: Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes, 40: 223-226, 1991
14. Howey DV, Bowsher RR, Brunelle RL, Woodworth JR: [Lys(B28),Pro(B29)]-Human insulin. A rapidely absorbed analogue of human insulin. Diabetes 43: 396-402, 1994
15. Koch GG.: The use of non-parametric methods in the statistical analysis of the two period change-crossover design, Biometrics, 577-584, 1972
16. Skyler JS, Skyler DL, Seigler DE, O'Sullivan MJ: Algorithms for adjustment of insulin dosage by patients monitor blood glucose. Diabetes care 4: 311-318, 1981
17. Taulbee JD: A not on the use of nonparametric methods in the statistical analysis of the two-period changeover design. Biometrics 38: 1053-1055, 1982
18. TerBraak EW, Bianchi R, Erkelenz DW: Faster, shorter and more profund action of Lys(B28),Pro(B29) human insulin analogue compared to regular insulin irrespective of the injection site. Diabetes 42 (Suppl.2): 207A, 1993
19. The DCCT Research Group: The effect of intensive treatment of diabetes on the developement and progression of long-term complications in insulin-dependent diabetes mellitus, N Engl J Med 329: 977-986, 1993
20. Torlone E, Fanelli C, Rambotti AM, Kassi G, Modarelli F, DiVincenzo A, Epifano L, Ciofetta M, Pampanelli S, Brunetti P, Bolli GB: Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM. Diabetobgia 37: 713-720, 1994
21. Trautmann ME, Attanasio A, Schulze-Schleppinghoff B, Stiller R, Niederreiter B, Haselbeck M: Blood sugar control during treatment with an insulin analogue, Diabetologia 36 (Suppl. 1): A155, 1993
22. Trautmann ME: Effect of the insulin analogue [Lys(B28),Pro(B29)] on blood glucose control. Horm Metab Res 26: 588-590, 1994
23. Woodworth JR, Howey DC, Bowsher R, Lutz S, Santa P, Brady P: [Lys±B28),Pro±B29)] Human insulin: dose ranging vs. Humulin R, Diabetes. 42 (Suppl. 2): 54A, 1993